LY3295668 is primarily investigated for its potential therapeutic applications in the treatment of cancer. It functions as an AKT inhibitor, targeting the AKT signaling pathway, which plays a critical role in cell survival, growth, and proliferation. By inhibiting this pathway, LY3295668 aims to suppress tumor growth and enhance the efficacy of other cancer treatments, such as chemotherapy or radiation therapy. Its application is particularly relevant in cancers where the AKT pathway is hyperactivated, including breast, prostate, and ovarian cancers. Research is ongoing to evaluate its safety, efficacy, and potential as part of combination therapies in clinical trials.